Gilbert syndrome and ischemic heart disease: a protective effect of elevated bilirubin levels


      Background: Oxidation processes play an important role in atherogenesis. Bilirubin IXα is recognised as a potent antioxidant. In the present study, we assessed the role of elevated serum bilirubin levels in the prevention of ischemic heart disease (IHD). Methods: The occurrence of IHD was determined in Gilbert syndrome (GS) patients above 40 years (n=50). The diagnosis was based on past medical history and ECG criteria. The occurrence was related to that of the comparable general population (n=2296). Serum biochemistry, including the total antioxidant status was evaluated in the GS subjects, IHD patients (n=38) and control subjects (n=38). Results: The prevalence of IHD in GS subjects (aged 49.7±9.0 years) was 2% (0.05–10.7%, 95% confidence interval), compared to 12.1% in a general population (P<0.05). Bilirubin, total antioxidant capacity and high density lipoprotein (HDL) cholesterol were found to be significantly higher in GS subjects compared to control groups (P<0.05). According to linear discriminant analysis, hyperbilirubinemia rather than elevation of HDL cholesterol levels seemed to be more important in protection from IHD. Conclusions: In the present study, low prevalence of IHD in GS subjects was detected. It may be presumed that chronic hyperbilirubinemia prevent the development of IHD by increasing the serum antioxidant capacity.



      CI, confidence interval (), GS, Gilbert syndrome (), HDL, high density lipoprotein (), HO, heme-oxygenase (), IHD, ischemic heart disease (), LDL, low density lipoprotein (), SRBI, scavenger receptor BI (), TAS, total antioxidant status (), UCB, unconjugated bilirubin ()
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Ross R.
        The pathogenesis of atherosclerosis: a perspective for the 1990s.
        Nature. 1993; 362: 801-809
        • Aviram M.
        Modified forms of low density lipoprotein and atherosclerosis.
        Atherosclerosis. 1993; 98: 1-9
        • van Hinsbergh V.W.M.
        • Scheffer M.
        • Havekes L.
        • Kempen H.J.M.
        Role of endothelial cells and their products in the modification of low-density lipoproteins.
        Biochim. Biophys. Acta. 1986; 878: 49-64
        • Gibaldi M.
        Antioxidant vitamins and health.
        J. Clin. Pharmacol. 1996; 36: 1093-1099
        • Esterbauer H.
        • Gebicki J.
        • Puhl H.
        • Jürgens G.
        The role of lipid peroxidation and antioxidants in oxidative modification of LDL.
        Free Rad. Biol. Med. 1992; 13: 341-390
        • Gutteridge J.M.C.
        Antioxidant properties of the proteins caeruloplasmin, albumin and transferrin. A study of their activity in serum and synovial fluid from patients with rheumatoid arthritis.
        Biochim. Biophys. Acta. 1986; 869: 119-127
        • Becker B.
        Towards the physiological function of uric acid.
        Free Rad. Biol. 1993; 14: 615-631
        • Stocker R.
        • Yamamoto Y.
        • McDonagh A.
        • Glazer A.N.
        • Ames N.B.
        Bilirubin is an antioxidant of possible physiological importance.
        Science. 1987; 235: 1043-1046
        • Maines M.D.
        The heme oxygenase system: a regulator of second messenger gases.
        Ann. Rev. Pharmacol. Toxicol. 1997; 37: 517-554
        • McCoubrey Jr, W.K.
        • Huang T.J.
        • Maines M.D.
        Isolation and characterization of cDNA from the rat brain that encodes hemoprotein heme oxygenase-3.
        Eur. J. Biochem. 1997; 247: 725-732
        • Motterlini R.
        • Foresti R.
        • Intaglietta M.
        • Winslow R.M.
        NO-mediated activation of heme-oxygenase: endogenous cytoprotection against oxidative stress to endothelium.
        Am. J. Physiol. Heart Circ. Physiol. 1996; 270: H107-H114
        • Neužil J.
        • Stocker R.
        Free and albumin-bound bilirubin are efficient co-antioxidants for α-tocoferol, inhibiting plasma and low density lipoprotein lipid peroxidation.
        J. Biol. Chem. 1994; 269: 16712-16719
        • Hulea S.A.
        • Wasowitz E.
        • Kummerow F.A.
        Inhibition of metal catalyzed oxidation of low-density lipoprotein by free and albumin bound bilirubin.
        Biochim. Biophys. Acta. 1995; 1259: 29-38
        • Wu T.W.
        • Fung K.P.
        • Wu J.
        • Yang C.C.
        • Weisel R.D.
        Antioxidation of human low density lipoprotein by unconjugated and conjugated bilirubins.
        Biochem. Pharmacol. 1996; 5l: 859-862
        • Wu T.W.
        • Fung K.P.
        • Yang C.C.
        Unconjugated bilirubin inhibits the oxidation of human low density lipoprotein better than Trolox.
        Life Sci. 1994; 54: 477-481
        • Minetti M.
        • Mallozzi C.
        • DiStasi A.M.M.
        • Pietroforte D.
        Bilirubin is an effective antioxidant of peroxynitrite mediated protein oxidation in human blood plasma.
        Arch. Biochem. Biophys. 1998; 352: 167-174
        • Yamaguchi T.
        • Terakado M.
        • Horio F.
        • Aoki K.
        • Tanaka M.
        • Nakajima H.
        Role of bilirubin as an antioxidant in an ischemia-reperfusion of rat liver and induction of heme oxygenase.
        Biochem. Biophys. Res. Commun. 1996; 223: 129-135
        • Dennery P.A.
        • McDonagh A.F.
        • Spitz D.R.
        • Rodgers P.A.
        • Stevenson D.K.
        Hyperbilirubinemia results in reduced oxidative injury in neonatal Gunn rats exposed to hyperoxia.
        Free. Rad. Biol. Med. 1995; 19: 395-404
        • Gopinathan V.
        • Miller J.N.
        • Milner A.D.
        • Rice-Evans C.A.
        Bilirubin and ascorbate antioxidant activity in neonatal plasma.
        FEBS Lett. 1994; 349: 197-200
        • Benaron D.A.
        • Bowen F.W.
        Variation of initial serum bilirubin rise in newborn infants with type of illness.
        Lancet. 1991; 338: 78-81
        • Schwertner H.A.
        • Jackson W.G.
        • Tolan G.
        Association of low serum concentration of bilirubin with increased risk of coronary artery disease.
        Clin. Chem. 1994; 40: 18-23
        • Breimer L.H.
        • Wannamethee G.
        • Ebrahim S.
        • Shaper A.G.
        Serum bilirubin and risk of ischemic heart disease in middle-aged British men.
        Clin. Chem. 1995; 41: 1504-1508
        • Hopkins P.N.
        • Wu L.L.
        • Hunt S.C.
        • James B.C.
        • Vincent M.C.
        • Wiliams R.R.
        Higher serum bilirubin is associated with decreased risk for early familial coronary artery disease.
        Arteroscler. Thromb. Vasc. Biol. 1996; 16: 250-255
        • Levinson S.S.
        Relationship between bilirubin, apolipoprotein B, and coronary artery disease.
        Ann. Clin. Lab. Sci. 1997; 27: 185-192
        • Madhavan M.
        • Wattigney W.A.
        • Srinivasan S.R.
        • Berenson G.S.
        Serum bilirubin distribution and its relation to cardiovascular risk in children and young adults.
        Atherosclerosis. 1997; 131: 107-113
        • Nakagami T.
        • Toyomura K.
        • Kinoshita T.
        • Morisawa S.
        A beneficial role of bile pigments as an endogenous tissue protector: anticomplement effects of biliverdin and conjugated bilirubin.
        Biochim. Biophys. Acta. 1993; 1158: 189-193
        • Tögl-Leimuller A.
        • Egger G.
        • Porta S.
        Albumin as a one way transport vehicle into sites of inflammation.
        Exp. Pathol. 1986; 30: 91-96
        • Galley H.F.
        • Thorton J.
        • Howdle P.D.
        • Walker B.E.
        • Webster N.R.
        Combination oral antioxidant supplementation reduces blood pressure.
        Clin. Sci. 1992; 4: 361-365
        • Bosma P.J.
        • Chowdhury J.R.
        • Bakker C.
        • et al.
        The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert syndrome.
        N. Engl. J. Med. 1995; 333: 1171-1175
      1. (a)
        • Douglas G.A.
        Practical statistics for medical research. Chapman & Hall, London1994: 93-96
      2. (b)
        • Douglas G.A.
        Practical statistics for medical research. Chapman & Hall, London1994: 143-145
      3. (c)
        • Douglas G.A.
        Practical statistics for medical research. Chapman & Hall, London1994: 325-336
      4. (d)
        • Douglas G.A.
        Practical statistics for medical research. Chapman & Hall, London1994: 358-360
        • Anderson K.M.
        • Wilson P.W.
        • Odell P.M.
        • Kannel W.B.
        An updated coronary risk profile. A statement for health professionals.
        Circulation. 1991; 83: 356-362
        • Geizerová H.
        • Widimský J.
        Některé aspekty primárnı́ prevence ICHS.
        Prakt Lék. 1974; 54: 87-91
        • Ostrowska A.
        • Tyszko P.
        Incidence of ischemic heart disease symptoms among residents of Plock and Kutno.
        Pol. Tyg. Lek. 1994; 49: 566-569
        • Lipovetskii B.M.
        • Plavinskaia S.I.
        • Ilina G.N.
        Clinicoepidemiological characteristics of ischemic heart disease in men of different age groups from the data of a single screening of a random population.
        Kardiologia. 1983; 23: 81-85
        • Marcowitz P.A.
        • Shayna V.
        • Horn R.A.
        • Hepner A.
        • Armstrong W.F.
        Value of dobutamine stress echocardiography in determining the prognosis of patients with known or suspect coronary artery disease.
        Am. J. Cardiol. 1996; 78: 404-408
        • Eichholzer M.
        • Stähelin H.B.
        • Gey F.
        Inverse correlation between essential antioxidants in plasma and subsequent risk to develop cancer, ischemic heart disease and stroke respectively: 12-year follow-up of the prospective basel study.
        Free Rad. Aging. 1992; 62: 398-410
        • Palgi A.
        Association between dietary changes and mortality rates; Israel 1949–1977; a trend free regression model.
        Am. J. Clin. Nutr. 1981; 34: 1569-1583
        • Ginter E.
        Decline of coronary mortality in United States and vitamin C.
        Am. J. Clin. Nutr. 1979; 32: 511-512
        • Gey K.F.
        • Brubacher G.B.
        • Stähelin H.B.
        Plasma levels of antioxidant vitamins in relation to ischemic heart disease and cancer.
        Am. J. Clin. Nutr. 1987; 45: 1368-1377
        • Bowry V.W.
        • Stanley K.K.
        • Stocker R.
        High density lipoprotein is the major carrier of lipid hydroperoxides in human blood plasma from fasting donors.
        Proc. Natl. Acad. Sci. USA. 1992; 89: 10316-10320
        • Fluiter K.
        • Sattler W.
        • De Beer M.C.
        • Connell P.M.
        • van der Westhuyzen D.R.
        • van Berkel T.J.
        Scavenger receptor BI mediates the selective uptake of oxidized cholesterol esters by rat liver.
        J. Biol. Chem. 1999; 274: 8893-8899
        • Rice Evans C.A.
        • Miller N.J.
        Total antioxidant status in plasma and body fluids.
        Meth. Enzymol. 1994; 234: 279-293
        • Belanger S.
        • Lavoie J.C.
        • Chessex P.
        Influence of bilirubin on the antioxidant capacity of plasma in newborn infants.
        Biol. Neon. 1997; 71: 233-238
        • Dailly E.
        • Urien S.
        • Barre J.
        • Reinert P.
        • Tillement J.P.
        Role of bilirubin in the regulation of the total peroxyl radical trapping antioxidant activity of plasma in sickle cell disease.
        Biochem. Biophys. Res. Commun. 1998; 248: 303-306
        • Clark J.E.
        • Foresti R.
        • Sarathchandra P.
        • Kaur H.
        • Green C.J.
        • Motterlini R.
        Heme oxygenase-1-derived bilirubin ameliorates postischemic myocardial dysfunction.
        Am. J. Physiol. Heart Circ. Physiol. 2000; 278: H643-H651
        • Raju V.S.
        • Imai N.
        • Liang C.S.
        Chamber-specific regulation of heme oxygenase-l (heat shock protein 32) in right-sided congestive heart failure.
        J. Mol. Cell Cardiol. 1999; 31: 1581-1589
        • Sharma H.S.
        • Manlik N.
        • Gho B.C.
        • Das D.K.
        • Verdouw P.D.
        Coordinated expression of heme oxygenase-1 and ubiquitin in the porcine heart subjected to ischemia and reperfusion.
        Mol. Cell. Biochem. 1996; 157: 111-116
        • Raju V.S.
        • Maines M.D.
        Renal ischemia/reperfusion up-regulates heme oxygenase-l (H5P32) expression and increases cGMP in rat heart.
        J. Pharm. Exp. Ther. 1996; 277: 1814-1822
        • Ishizaka N.
        • de Leon H.
        • Laursen J.B.
        • et al.
        Angiotensin II-induced hypertension increases heme oxygenase-1 expression in rat aorta.
        Circulation. 1997; 96: 1923-1929
        • Hanckock W.W.
        • Buelow R.
        • Sayegh M.H.
        • Turka L.A.
        Antibody-induced transplant arteriosclerosis is prevented by graft expression of antioxidant and antiapoptotic genes.
        Nat. Med. 1998; 4: 1392-1396
        • Sharma S.C.
        Serum unconjugated bilirubin and free fatty acids in acute myocardial infarction and angina.
        J. Assoc. Physicians India. 1985; 33: 473-475
        • Schwertner H.A.
        • Fischer Jr, J.R.
        Comparison of various lipid, lipoprotein, and bilirubin combinations as risk factors for predicting coronary artery disease.
        Atherosclerosis. 2000; 150: 381-387